Evoke Pharma, Inc. (NASDAQ:EVOK) will post its quarterly earnings results after the market closes on Monday, August 14th. Analysts expect Evoke Pharma to post earnings of ($0.15) per share for the quarter.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Monday, May 15th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same period in the prior year, the company posted ($0.45) earnings per share. On average, analysts expect Evoke Pharma to post $-0.72 EPS for the current fiscal year and $0.34 EPS for the next fiscal year.
Evoke Pharma, Inc. (NASDAQ EVOK) opened at 2.24 on Friday. The company’s market cap is $34.47 million. The firm has a 50-day moving average price of $2.46 and a 200-day moving average price of $2.72. Evoke Pharma, Inc. has a 52 week low of $1.35 and a 52 week high of $4.55.
A hedge fund recently raised its stake in Evoke Pharma stock. Vanguard Group Inc. boosted its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 15.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 523,650 shares of the specialty pharmaceutical company’s stock after buying an additional 68,544 shares during the period. Vanguard Group Inc. owned about 3.40% of Evoke Pharma worth $1,341,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.40% of the company’s stock.
Several analysts recently commented on EVOK shares. FBR & Co reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Evoke Pharma in a report on Thursday, May 18th. ValuEngine raised Evoke Pharma from a “sell” rating to a “hold” rating in a report on Thursday, July 20th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $7.25.
ILLEGAL ACTIVITY NOTICE: “Evoke Pharma, Inc. (NASDAQ:EVOK) Set to Announce Quarterly Earnings on Monday” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://transcriptdaily.com/2017/08/13/evoke-pharma-inc-nasdaqevok-set-to-announce-quarterly-earnings-on-monday.html.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.